Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. on November 9, 2018, reporting events as of November 7, 2018. The filing serves to announce company highlights and financial results for the third quarter ended September 30, 2018. Note: The input metadata references "Cardiff Oncology, Inc.," but the filing text explicitly identifies the registrant as Trovagene, Inc.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period within the text body. It solely references the issuance of a press release containing the third-quarter results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information disclosed under Item 2.02 and Exhibit 99.1 is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not incorporated by reference into other registration statements unless expressly set forth. No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing the attached Exhibit 99.1 (Press Release dated November 7, 2018).
- Confirm the corporate identity, as the filing is for Trovagene, Inc., not Cardiff Oncology, Inc.
- Review the full press release for any operational updates or clinical trial milestones not summarized in this 8-K.
- Note that the financial data in this filing is not legally "filed" for liability purposes under Section 18 of the Exchange Act.